So far four different CD19-specific CAR T cells have been approved against indications of diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), mantle cell lymphoma (MCL), and follicular lymphoma1–4. Here, CD19 is linked to mantle cell lymphoma.